Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) "PRISM II"

Active, not recruiting

Phase 4 Results N/A

Eligibility Criteria

Inclusion Criteria

- Center for Neurologic Study-Lability Scale (CNS-LS)score of 13 or greater
- Clinical diagnosis of Pseudobulbar Affect (PBA)
- Documentation of Neurologic disease or brain injury

Exclusion Criteria

- Unstable neurologic disease
- Severe dementia
- Stroke within 3 months
- Penetrating TBI
- Contraindications to Nuedexta
- Severe Depressive Disorder